Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Cancer Immunology ImmunotherapyOpen Access

GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMarta KłopotowskaIBIwona BaranowskaSHStephen L. Hajduk

Discussion

Loading...

Member takes

Overview

This analysis reveals GPX4 as a central regulator affecting T cells and CAR-T cells susceptibility to ferroptosis, highlighting implications for immunotherapy.

Key Points

  • GPX4 is identified as a master regulator affecting T and CAR-T cell sensitivity to ferroptosis.
  • The study found CD8⁺ EM and TEMRA cells to be most sensitive to ferroptosis, influencing immunotherapy outcomes.
  • Inducing ferroptosis in tumor cells enhances immunotherapy effectiveness, but may limit CAR-T cell functions if not carefully managed.
  • The findings suggest strategies to lessen CAR-T cells' sensitivity to ferroptosis can improve their therapeutic value.

Cite This Study

Kłopotowska et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479ccd7https://doi.org/10.1007/s00262-025-04133-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1GPX4 in the Tumor Microenvironment: Not Just Inhibiting Ferroptosis, but Immuno-Metabolic Regulation2026 · 1 citations
  2. 2Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity2025 · 5 citations
  3. 3Lipid Composition Alters Ferroptosis Sensitivity2025 · 27 citations
  4. 4Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia2025 · 1 citations
  5. 5Ferroptosis’s Master Switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with in vitro experiments validation2025 · 4 citations